Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1983 Jul;53(1):1–9.

Circulating thymic hormone levels in severe combined immunodeficiency.

T Iwata, G S Incefy, R A Good, S Cunningham-Rundles, M Dardenne, N Kapoor, D Kirkpatrick, R J O'Reilly
PMCID: PMC1535544  PMID: 6347473

Abstract

Twenty-three patients with severe combined immunodeficiency disease were studied for circulating thymic hormone levels (facteur thymique serique, FTS), 21 prior to treatment by transplantation of bone marrow, thymus or fetal liver. Thirteen showed undetectable FTS activity. Only two had normal levels of this hormone. In serial determinations of FTS activity prior to and after transplantation, patients given bone marrow transplants developed sustained increments of serum FTS activity early in the course of their immunological reconstitution. However, patients given transplants of fetal liver alone or fetal liver plus thymus from fetuses of less than 12 weeks gestation generally did not show an increment of FTS activity during the period of observation. Transplantation of irradiated thymus derived from fetuses of more than 14 weeks gestation produced sustained increases of thymic hormone activity. These observations suggest that a cell of haematopoietic origin provides a stimulus necessary for differentiation or maturation of thymic secretory activity and that this cell(s) is present in post-natal marrow, but is either undeveloped or immature in the early fetal liver or fails to migrate to the thymus of an allogeneic host.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bach J., Bardenne M., Pleau J., Rosa J. Biochemical characterisation of a serum thymic factor. Nature. 1977 Mar 3;266(5597):55–57. doi: 10.1038/266055a0. [DOI] [PubMed] [Google Scholar]
  2. Bentwich Z., Douglas S. D., Siegal F. P., Kunkel H. G. Human lymphocyte-sheep erythrocyte rosette formation: some characteristics of the interaction. Clin Immunol Immunopathol. 1973 Jul;1(4):511–522. doi: 10.1016/0090-1229(73)90007-x. [DOI] [PubMed] [Google Scholar]
  3. Dardenne M., Pléau J. M., Bach J. F. Evidence of the presence in normal serum of a carrier of the serum thymic factor (FTS). Eur J Immunol. 1980 Feb;10(2):83–86. doi: 10.1002/eji.1830100203. [DOI] [PubMed] [Google Scholar]
  4. Identification, enumeration, and isolation of B and T lymphocytes from human peripheral blood. Report of a WHO-IARC-sponsored workshop on human B and T cells, London, 15-17 July 1974. Scand J Immunol. 1974;3(5):521–532. [PubMed] [Google Scholar]
  5. Incefy G. S., Dardenne M., Pahwa S., Grimes E., Pahwa R. N., Smithwick E., O'Reilly R., Good R. A. Thymic activity in severe combined immunodeficiency diseases. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1250–1253. doi: 10.1073/pnas.74.3.1250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Incefy G. S., Mertelsmann R., Yata K., Dardenne M., Bach J. F., Good R. A. Induction of differentiation in human marrow T cell precursors by the synthetic serum thymic factor, FTS. Clin Exp Immunol. 1980 May;40(2):396–406. [PMC free article] [PubMed] [Google Scholar]
  7. Incefy G. S., O'Reilly R. J., Kapoor N., Iwata T., Good R. A. In vitro differentiation of human marrow T cell precursors by thymic factors in severe combined immunodeficiency. Transplantation. 1981 Oct;32(4):299–305. doi: 10.1097/00007890-198110000-00008. [DOI] [PubMed] [Google Scholar]
  8. Iwata T., Incefy G. S., Cunningham-Rundles S., Cunningham-Rundles C., Smithwick E., Geller N., O'Reilly R., Good R. A. Circulating thymic hormone activity in patients with primary and secondary immunodeficiency diseases. Am J Med. 1981 Sep;71(3):385–394. doi: 10.1016/0002-9343(81)90164-9. [DOI] [PubMed] [Google Scholar]
  9. Meuwissen H. J., Pollara B., Pickering R. J. Combined immunodeficiency disease associated with adenosine deaminase deficiency. Report on a workshop held in Albany, New York, October 1, 1973. J Pediatr. 1975 Feb;86(2):169–181. doi: 10.1016/s0022-3476(75)80463-x. [DOI] [PubMed] [Google Scholar]
  10. Monier J. C., Dardenne M., Pléau J. M., Schmitt D., Deschaux P., Bach J. F. Characterization of facteur thymique sérique (FTS) in the thymus. I. Fixation of anti-FTS antibodies on thymic reticulo-epithelial cells. Clin Exp Immunol. 1980 Dec;42(3):470–476. [PMC free article] [PubMed] [Google Scholar]
  11. Pollack M. S., Kapoor N., Sorell M., Kim S. J., Christiansen F. T., Silver D. M., Dupont B., O'Reilly R. J. DR-positive maternal engrafted T cells in a severe combined immunodeficiency patient without graft-versus-host disease. Transplantation. 1980 Nov;30(5):331–334. doi: 10.1097/00007890-198011000-00004. [DOI] [PubMed] [Google Scholar]
  12. Preud'homme J. L., Seligmann M. Surface bound immunoglobulins as a cell marker in human lymphoproliferative diseases. Blood. 1972 Dec;40(6):777–794. [PubMed] [Google Scholar]
  13. Pyke K. W., Dosch H., Ipp M. M., Gelfand E. W. Demonstration of an intrathymic defect in a case of severe combined immunodeficiency disease. N Engl J Med. 1975 Aug 28;293(9):424–428. doi: 10.1056/NEJM197508282930904. [DOI] [PubMed] [Google Scholar]
  14. Savino W., Dardenne M., Papiernik M., Bach J. F. Thymic hormone-containing cells. Characterization and localization of serum thymic factor in young mouse thymus studied by monoclonal antibodies. J Exp Med. 1982 Aug 1;156(2):628–633. doi: 10.1084/jem.156.2.628. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES